Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Randomized, Double-Blind, Placebo- and Active-Controlled Study to Assess the Efficacy and Safety of NBI-56418 in Subjects With Endometriosis

Trial Profile

A Phase II, Randomized, Double-Blind, Placebo- and Active-Controlled Study to Assess the Efficacy and Safety of NBI-56418 in Subjects With Endometriosis

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Oct 2018

At a glance

  • Drugs Elagolix (Primary) ; Leuprorelin
  • Indications Endometriosis
  • Focus Therapeutic Use
  • Acronyms TULIP-PETAL
  • Sponsors Neurocrine Biosciences
  • Most Recent Events

    • 10 Oct 2018 Results assessing the the degree of estradiol suppression following treatment with elagolix or LA in women with endometriosis-associated pain, presented at the American Society for Reproductive Medicine Scientific Congress 2018
    • 26 Jun 2012 Results assessing the effects of treatment on BMD presented at the 94th Annual Meeting of the Endocrine Society.
    • 03 Feb 2012 Company (Abbott Laboratories) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top